New Risk • Apr 03
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩122.7b market cap, or US$81.3m). Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩1,555, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 18% over the past three years. お知らせ • Mar 13
Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026 Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: dasan hall, 114, taebong-ro, seocho-gu, seoul South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₩1,299, the stock trades at a trailing P/E ratio of 58.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩1,532, the stock trades at a trailing P/E ratio of 68.9x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 24% over the past three years. New Risk • Dec 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩104.9b market cap, or US$72.7m). Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩1,194, the stock trades at a trailing P/E ratio of 53.7x. Average trailing P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 33% over the past three years. Reported Earnings • Nov 20
Third quarter 2025 earnings released: EPS: ₩15.00 (vs ₩17.00 loss in 3Q 2024) Third quarter 2025 results: EPS: ₩15.00 (up from ₩17.00 loss in 3Q 2024). Revenue: ₩6.01b (up 151% from 3Q 2024). Net income: ₩1.36b (up ₩2.89b from 3Q 2024). Profit margin: 23% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩90.7b market cap, or US$65.4m). New Risk • Apr 01
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$53.2m). お知らせ • Mar 01
Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025 Aminologics Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea Reported Earnings • Nov 12
Third quarter 2024 earnings released: ₩17.00 loss per share (vs ₩6.00 loss in 3Q 2023) Third quarter 2024 results: ₩17.00 loss per share (further deteriorated from ₩6.00 loss in 3Q 2023). Revenue: ₩2.39b (down 43% from 3Q 2023). Net loss: ₩1.53b (loss widened 177% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩102.1b market cap, or US$77.6m). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩1,157, the stock trades at a trailing P/E ratio of 39.5x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 61% over the past three years. Reported Earnings • Mar 26
Full year 2023 earnings released: EPS: ₩28.00 (vs ₩83.00 loss in FY 2022) Full year 2023 results: EPS: ₩28.00 (up from ₩83.00 loss in FY 2022). Revenue: ₩20.9b (down 24% from FY 2022). Net income: ₩2.44b (up ₩9.72b from FY 2022). Profit margin: 12% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. New Risk • Jul 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩123.4b (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩123.4b market cap, or US$96.4m). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₩2,465, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 18% share price gain to ₩2,845, the stock trades at a trailing P/E ratio of 32.4x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 20% share price gain to ₩2,645, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improved over the past week After last week's 17% share price gain to ₩2,310, the stock trades at a trailing P/E ratio of 37.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 5.0% over the past three years. Reported Earnings • Nov 13
Third quarter 2021 earnings released: EPS ₩11.00 (vs ₩8.00 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₩4.41b (down 15% from 3Q 2020). Net income: ₩961.5m (up 35% from 3Q 2020). Profit margin: 22% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩2,345, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 8.1% over the past three years. Reported Earnings • May 19
First quarter 2021 earnings released: EPS ₩10.00 (vs ₩5.00 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩4.41b (up 8.5% from 1Q 2020). Net income: ₩869.4m (up ₩1.30b from 1Q 2020). Profit margin: 20% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₩24.00 (vs ₩14.00 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₩17.7b (down 7.0% from FY 2019). Net income: ₩2.14b (up ₩3.34b from FY 2019). Profit margin: 12% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 09
New 90-day low: ₩2,400 The company is down 19% from its price of ₩2,970 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Jan 06
New 90-day high: ₩3,405 The company is up 49% from its price of ₩2,285 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period. Is New 90 Day High Low • Dec 04
New 90-day high: ₩2,740 The company is up 13% from its price of ₩2,415 on 04 September 2020. The South Korean market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Oct 18
New 90-day low: ₩2,030 The company is down 2.0% from its price of ₩2,080 on 20 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period. 
